Holen Sie sich die Stockscreener-App
26.76
1.48%
0.39
Handel nachbörslich:
26.76
Schlusskurs vom Vortag:
$26.37
Offen:
$26.27
24-Stunden-Volumen:
232.88K
Relative Volume:
1.14
Marktkapitalisierung:
$1.76B
Einnahmen:
$282.04M
Nettoeinkommen (Verlust:
$221.88M
KGV:
-11.42
EPS:
-2.3434
Netto-Cashflow:
$-449.57M
1W Leistung:
-0.22%
1M Leistung:
+4.37%
6M Leistung:
+4.41%
1J Leistung:
-31.40%
1-Tages-Spanne:
$26.14
$27.00
1-Wochen-Bereich:
$26.12
$27.27
52-Wochen-Spanne:
$24.16
$42.45
Galapagos Nv Adr Stock (GLPG) Company Profile
Firmenname
Galapagos Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLPG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
26.76 | 1.76B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-20 | Herabstufung | Kepler | Hold → Reduce |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-04-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Eingeleitet | Maxim Group | Buy |
| 2020-10-21 | Herabstufung | Goldman | Neutral → Sell |
| 2020-08-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-07-10 | Herabstufung | Stifel | Buy → Hold |
| 2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-07-31 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-29 | Herabstufung | Jefferies | Buy → Hold |
Alle ansehen
Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma - GlobeNewswire Inc.
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.32% By Investing.com - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen By Investing.com - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
Earnings call: Galapagos outlines strategic focus in Q1 2024 results By Investing.com - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Allied Gaming & Entertainment insider buys shares worth over $456,000 By Investing.com - Investing.com
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares - Yahoo Finance
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
AIM tech shares that broke America - Interactive Investor
Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
GalapagosAll Time High - Seeking Alpha
Galapagos NV ADR (NQ: GLPG - Financial Content
Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):